STOCK TITAN

Ovid Therapeutics: RA Capital reports 7.8% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Ovid Therapeutics Inc. (OVID) is named in an amended Schedule 13G reporting that RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund, L.P. each reported beneficial ownership of 15,968,626 shares, or 7.8%, as of September 30, 2026. The Fund directly held 5,598,200 common shares, plus pre-funded warrants exercisable for up to 5,013,426 shares and Series B common warrants exercisable for up to 5,357,000 shares.

The reporting persons listed shared voting and dispositive power over the reported amount. The Fund stated it delegated voting and investment power to RA Capital and disclaimed beneficial ownership; the percentage calculation uses 195,297,857 common shares outstanding as of August 11, 2026, giving effect to the warrants.

Beneficial ownership reported 15,968,626 shares Each of the four reporting persons reported this amount as of September 30, 2026; includes warrant shares.
Reported ownership percentage 7.8% Reported as of September 30, 2026; calculated giving effect to warrants.
Common shares held directly by the Fund 5,598,200 shares RA Capital Healthcare Fund, L.P. directly held these common shares.
Pre-funded warrant shares Up to 5,013,426 shares Shares underlying warrants immediately exercisable by the Fund.
Series B common warrant shares Up to 5,357,000 shares Shares underlying warrants immediately exercisable by the Fund.
Common shares outstanding 195,297,857 shares As of August 11, 2026; basis for the reported ownership percentage, giving effect to warrants.
beneficial ownership regulatory
"aggregate number of shares ... beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Pre-Funded Warrants financial
"pre-funded warrants immediately exercisable for up to 5,013,426 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Series B Common Warrants financial
"Series B warrants immediately exercisable for up to 5,357,000 shares"
Series B common warrants are rights issued alongside a Series B financing that let the holder buy a company’s common shares at a fixed price before a set expiration date. Think of them like a coupon giving the option to purchase stock later at a pre-agreed price; if the stock rises above that price the warrants can be exercised for profit, but if not they expire worthless. Investors watch them because exercising or selling warrants can dilute existing ownership, change share count and bring immediate cash to the company, affecting valuation and investor returns.
shared voting power regulatory
"Shared Voting Power 15,968,626.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Section 13(d) regulatory
"for purposes of Section 13(d) of the Act"
A Section 13(d) filing is a public disclosure required under U.S. securities law when a person or group acquires more than 5% of a company’s registered equity and may influence control. The filer must report who owns the shares, how they were acquired, and any plans or intentions for the company, so the market and other shareholders can see if a large buyer is attempting a takeover or other strategic move. Think of it like a formal announcement that someone has crossed a threshold and is showing their hand.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How was the reported 7.8% OVID ownership calculated?

The percentage was based on 195,297,857 common shares outstanding as of August 11, 2026, giving effect to the warrants. The reported ownership date was September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





690469101

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



RA Capital Management, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By Peter Kolchinsky, Authorized Signatory
Date:11/16/2026
Peter Kolchinsky
Signature:/s/ Peter Kolchinsky
Name/Title:Peter Kolchinsky
Date:11/16/2026
Rajeev Shah
Signature:/s/ Rajeev Shah
Name/Title:Rajeev Shah
Date:11/16/2026
RA Capital Healthcare Fund, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date:11/16/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on December 18, 2025).

Keep reading